查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951763

合約開發和生產組織 (CDMO) 市場分析及至 2035 年預測：按類型、產品、服務、技術、應用、最終用戶、材料類型、階段、工藝和實施類型分類

Contract Development and Manufacturing Organization (CDMO) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Material Type, Stage, Process, Deployment
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

合約研發生產機構（CDMO）市場預計將從2024年的1,600億美元成長到2034年的3,150億美元，複合年成長率約為6.7%。 CDMO市場涵蓋為製藥和生物技術公司提供從藥物研發到生產的全方位服務的營業單位。 CDMO在製劑設計、製程開發和大規模生產方面擁有豐富的專業知識。該市場的成長動力來自外包趨勢、對成本效益的需求以及對專業化生產能力的需求，以促進創新並加快藥物上市速度。

受製藥生產外包日益成長的推動，合約研發生產機構 (CDMO) 市場持續穩定擴張。按服務細分，生物製藥的成長速度最快，這主要得益於市場對複雜生物製藥和生物相似藥的強勁需求。小分子藥物緊隨其後，在廣泛的治療應用領域保持著重要地位。在各個子細分領域中，原料原料藥)服務佔據主導地位，這主要得益於生物製藥生產所需的複雜製程。製劑服務位居第二，反映出市場對製劑開發和包裝解決方案的需求不斷成長。個人化醫療和先進治療方法的興起進一步推動了對專業 CDMO 服務的需求。一次性技術和連續生產等技術進步對於最佳化生產效率至關重要。策略夥伴關係和合作的重要性日益凸顯，使企業能夠利用互補的專業知識並擴展其服務範圍。隨著監管要求的不斷變化，CDMO 在確保合規性和加快產品上市速度方面仍然發揮著至關重要的作用。

市場區隔
類型 小分子藥物、生物製藥和先進治療藥物（ATMP）
產品 原料藥（API）、成品劑型（FDF）、中間體
服務 製程開發、分析服務、製造、包裝、法規支援、供應鏈管理
科技 生物製程、製劑、冷凍乾燥、連續生產
適應症 腫瘤學、心血管疾病、神經學、感染疾病、免疫學、呼吸系統疾病
最終用戶 製藥公司、生技公司和研究機構
材料類型 合成的、生物的
步 臨床前、臨床、商業化
過程 發酵、化學合成、細胞培養
部署 內部、外包

合約開發與生產組織 (CDMO) 市場的特徵是市場佔有率分佈多元化、定價策略多樣，以及新產品層出不窮。該行業的成長主要得益於製藥和生物技術行業對外包需求的不斷成長。各公司正利用創新技術提升產品和服務，以實現更具競爭力的價格和更優質的服務。策略聯盟和合作日益增多，促進了新產品和服務的推出。快速變化的客戶需求和技術進步進一步凸顯了市場的動態性。競爭標竿分析顯示，市場競爭異常激烈，主要企業在追求卓越營運和市場差異化。監管影響至關重要，嚴格的合規要求塑造企業的策略。儘管市場由少數主要企業主導，但新興企業也迅速崛起。北美和歐洲等地區的法規結構對於制定行業標準至關重要。在技​​術創新和對個人化醫療日益成長的關注的推動下，CDMO 市場預計將保持強勁成長。此外，企業還需應對複雜的法規環境並維持高標準的質量，這進一步加劇了競爭格局的複雜性。

主要趨勢和促進因素：

受幾項關鍵趨勢和促進因素的影響，合約研發生產機構 (CDMO) 市場正經歷強勁成長。首先，生物製藥和生物相似藥的需求不斷成長，這是一個顯著的趨勢。隨著製藥公司專注於創新治療方法，它們擴大轉向 CDMO 來管理複雜的生產流程，從而推動了市場成長。其次，製藥公司正在加速外包。透過利用 CDMO 的專業知識，這些公司可以縮短產品上市時間，並專注於自身的核心競爭力。這一趨勢在尋求成本效益解決方案的中小型企業中尤其明顯。第三，生產流程的技術進步正在改變 CDMO 的格局。連續生產和一次性使用技術等創新提高了效率和柔軟性，吸引了更多客戶選擇 CDMO。此外，個人化醫療的興起也推動了專業化生產能力的需求。最後，複雜的監管環境和嚴格的品質標準迫使製藥公司與 CDMO 合作。這些機構擁有必要的認證和專業知識，能夠應對監管環境，確保合規性並維持產品品質。這趨勢凸顯了CDMO在醫藥供應鏈中的戰略重要性。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 小分子藥物
    • 生物製藥
    • 先進療法藥物（ATMP）
  • 市場規模及預測：依產品分類
    • 原料藥（API）
    • 最終劑型（FDF）
    • 中級
  • 市場規模及預測：依服務分類
    • 製程開發
    • 分析服務
    • 製造業
    • 包裝
    • 監管支持
    • 供應鏈管理
  • 市場規模及預測：依技術分類
    • 生物製程
    • 配方
    • 冷凍乾燥
    • 連續製造
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經病學
    • 感染疾病
    • 免疫學
    • 呼吸系統疾病
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
  • 市場規模及預測：依材料類型分類
    • 合成
    • 生物製藥
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 臨床
    • 商業的
  • 市場規模及預測：依製程分類
    • 發酵
    • 化學合成
    • 細胞培養
  • 市場規模及預測：依發展狀況
    • 內部開發
    • 外包

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Catalent
  • Lonza Group
  • Recipharm
  • Siegfried Holding
  • Wu Xi App Tec
  • Samsung Biologics
  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim Bio Xcellence
  • Patheon
  • Corden Pharma
  • Ajinomoto Bio-Pharma Services
  • Alcami Corporation
  • Piramal Pharma Solutions
  • Jubilant Hollister Stier
  • Cambrex Corporation
  • AMRI Global
  • Thermo Fisher Scientific
  • Vetter Pharma International
  • PCI Pharma Services
  • LSNE Contract Manufacturing

第9章：關於我們

簡介目錄
Product Code: GIS21685

Contract Development and Manufacturing Organization (CDMO) Market is anticipated to expand from $160 billion in 2024 to $315 billion by 2034, growing at a CAGR of approximately 6.7%. The Contract Development and Manufacturing Organization (CDMO) Market encompasses entities providing comprehensive services from drug development to manufacturing for pharmaceutical and biotech firms. CDMOs offer expertise in formulation, process development, and large-scale production. The market is propelled by increasing outsourcing trends, cost-efficiency demands, and the need for specialized manufacturing capabilities, fostering innovation and accelerating drug time-to-market.

The Contract Development and Manufacturing Organization (CDMO) market is experiencing robust expansion, propelled by the increasing outsourcing of pharmaceutical manufacturing. Within the service segments, the biologics segment outperforms, driven by the surge in demand for complex biologic drugs and biosimilars. The small molecule segment follows, maintaining significance due to its broad therapeutic applications. In the sub-segments, drug substance services lead, fueled by the intricate processes required for biologic drug production. Drug product services are the second highest-performing sub-segment, reflecting the growing need for formulation development and packaging solutions. The rise of personalized medicine and advanced therapies further enhances the demand for specialized CDMO services. Technological advancements, such as single-use technologies and continuous manufacturing, are pivotal in optimizing production efficiency. Strategic partnerships and collaborations are becoming increasingly vital, enabling companies to leverage complementary expertise and expand their service offerings. As regulatory requirements evolve, CDMOs remain critical in ensuring compliance and accelerating time-to-market.

Market Segmentation
TypeSmall Molecule, Biologics, Advanced Therapy Medicinal Products (ATMPs)
ProductActive Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Intermediates
ServicesProcess Development, Analytical Services, Manufacturing, Packaging, Regulatory Support, Supply Chain Management
TechnologyBioprocessing, Formulation, Lyophilization, Continuous Manufacturing
ApplicationOncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Respiratory Diseases
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes
Material TypeSynthetic, Biological
StagePreclinical, Clinical, Commercial
ProcessFermentation, Chemical Synthesis, Cell Culture
DeploymentIn-house, Outsourced

The Contract Development and Manufacturing Organization (CDMO) market is characterized by a diverse landscape of market share distribution, pricing strategies, and a continuous stream of new product launches. The sector's growth is propelled by the increasing demand for outsourcing in pharmaceutical and biotechnology industries. Companies are leveraging innovative technologies to enhance their offerings, leading to competitive pricing and improved service delivery. The market is witnessing a surge in strategic partnerships and collaborations, which are fostering the introduction of novel products and services. The dynamic nature of this market is further accentuated by the rapid evolution of customer needs and technological advancements. Competition benchmarking reveals a highly competitive environment with key players striving to achieve operational excellence and market differentiation. Regulatory influences play a pivotal role, with stringent compliance requirements shaping operational strategies. The market is dominated by a few major players, yet emerging companies are making significant inroads. Regulatory frameworks in regions such as North America and Europe are pivotal in setting industry standards. The CDMO market is poised for robust growth, driven by technological innovations and an increasing focus on personalized medicine. The competitive landscape is further complicated by the need to navigate complex regulatory environments and maintain high-quality standards.

Geographical Overview:

The Contract Development and Manufacturing Organization (CDMO) market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced pharmaceutical innovations and significant investment in biotechnology. The presence of key industry players and a strong regulatory framework further bolster the market's expansion. Europe is experiencing substantial growth, fueled by increased demand for biologics and personalized medicine. The region's focus on sustainable manufacturing practices enhances its competitive edge. In the Asia Pacific, rapid industrialization and a burgeoning middle class are propelling market growth. Countries like China and India are emerging as pivotal players due to their expanding pharmaceutical sectors and cost-effective manufacturing capabilities. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improving healthcare infrastructure and rising investments in pharmaceutical research are driving growth. Meanwhile, the Middle East & Africa are recognizing the potential of CDMOs in fostering economic diversification and innovation.

The CDMO market is increasingly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with the US and China are prompting investments in local biopharmaceutical capabilities to mitigate reliance on foreign entities. China, facing heightened scrutiny and export controls, is accelerating its domestic CDMO infrastructure to support its burgeoning pharmaceutical sector. Taiwan remains pivotal in the CDMO landscape, yet is vulnerable to geopolitical risks, especially concerning cross-strait relations. Globally, the CDMO market is robust, driven by rising demand for biologics and personalized medicine. By 2035, the market's evolution will hinge on strategic regional partnerships and supply chain resilience. Middle East conflicts could disrupt global supply chains, affecting energy prices and operational costs, thus influencing CDMO market strategies.

Key Trends and Drivers:

The Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth due to several critical trends and drivers. Firstly, the increasing demand for biologics and biosimilars is a significant trend. As pharmaceutical companies focus on innovative therapies, they are turning to CDMOs to manage complex manufacturing processes, thus driving market growth. Secondly, the trend towards outsourcing by pharmaceutical companies is accelerating. By leveraging CDMO expertise, these companies can reduce time to market and focus on core competencies. This trend is particularly prominent among small and medium-sized enterprises seeking cost-effective solutions. Thirdly, technological advancements in manufacturing processes are transforming the CDMO landscape. Innovations such as continuous manufacturing and single-use technologies are enhancing efficiency and flexibility, attracting more clients to CDMOs. Additionally, the rise of personalized medicine is driving demand for specialized manufacturing capabilities. Finally, regulatory complexities and stringent quality standards are compelling pharmaceutical companies to collaborate with CDMOs. These organizations possess the necessary certifications and expertise to navigate regulatory landscapes, ensuring compliance and maintaining product quality. This trend underscores the strategic importance of CDMOs in the pharmaceutical supply chain.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Material Type
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Process
  • 2.10 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Small Molecule
    • 4.1.2 Biologics
    • 4.1.3 Advanced Therapy Medicinal Products (ATMPs)
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Active Pharmaceutical Ingredients (APIs)
    • 4.2.2 Finished Dosage Forms (FDFs)
    • 4.2.3 Intermediates
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Process Development
    • 4.3.2 Analytical Services
    • 4.3.3 Manufacturing
    • 4.3.4 Packaging
    • 4.3.5 Regulatory Support
    • 4.3.6 Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Bioprocessing
    • 4.4.2 Formulation
    • 4.4.3 Lyophilization
    • 4.4.4 Continuous Manufacturing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurology
    • 4.5.4 Infectious Diseases
    • 4.5.5 Immunology
    • 4.5.6 Respiratory Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
  • 4.7 Market Size & Forecast by Material Type (2020-2035)
    • 4.7.1 Synthetic
    • 4.7.2 Biological
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Fermentation
    • 4.9.2 Chemical Synthesis
    • 4.9.3 Cell Culture
  • 4.10 Market Size & Forecast by Deployment (2020-2035)
    • 4.10.1 In-house
    • 4.10.2 Outsourced

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Material Type
      • 5.2.1.8 Stage
      • 5.2.1.9 Process
      • 5.2.1.10 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Material Type
      • 5.2.2.8 Stage
      • 5.2.2.9 Process
      • 5.2.2.10 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Material Type
      • 5.2.3.8 Stage
      • 5.2.3.9 Process
      • 5.2.3.10 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Material Type
      • 5.3.1.8 Stage
      • 5.3.1.9 Process
      • 5.3.1.10 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Material Type
      • 5.3.2.8 Stage
      • 5.3.2.9 Process
      • 5.3.2.10 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Material Type
      • 5.3.3.8 Stage
      • 5.3.3.9 Process
      • 5.3.3.10 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Material Type
      • 5.4.1.8 Stage
      • 5.4.1.9 Process
      • 5.4.1.10 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Material Type
      • 5.4.2.8 Stage
      • 5.4.2.9 Process
      • 5.4.2.10 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Material Type
      • 5.4.3.8 Stage
      • 5.4.3.9 Process
      • 5.4.3.10 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Material Type
      • 5.4.4.8 Stage
      • 5.4.4.9 Process
      • 5.4.4.10 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Material Type
      • 5.4.5.8 Stage
      • 5.4.5.9 Process
      • 5.4.5.10 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Material Type
      • 5.4.6.8 Stage
      • 5.4.6.9 Process
      • 5.4.6.10 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Material Type
      • 5.4.7.8 Stage
      • 5.4.7.9 Process
      • 5.4.7.10 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Material Type
      • 5.5.1.8 Stage
      • 5.5.1.9 Process
      • 5.5.1.10 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Material Type
      • 5.5.2.8 Stage
      • 5.5.2.9 Process
      • 5.5.2.10 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Material Type
      • 5.5.3.8 Stage
      • 5.5.3.9 Process
      • 5.5.3.10 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Material Type
      • 5.5.4.8 Stage
      • 5.5.4.9 Process
      • 5.5.4.10 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Material Type
      • 5.5.5.8 Stage
      • 5.5.5.9 Process
      • 5.5.5.10 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Material Type
      • 5.5.6.8 Stage
      • 5.5.6.9 Process
      • 5.5.6.10 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Material Type
      • 5.6.1.8 Stage
      • 5.6.1.9 Process
      • 5.6.1.10 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Material Type
      • 5.6.2.8 Stage
      • 5.6.2.9 Process
      • 5.6.2.10 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Material Type
      • 5.6.3.8 Stage
      • 5.6.3.9 Process
      • 5.6.3.10 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Material Type
      • 5.6.4.8 Stage
      • 5.6.4.9 Process
      • 5.6.4.10 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Material Type
      • 5.6.5.8 Stage
      • 5.6.5.9 Process
      • 5.6.5.10 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Catalent
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza Group
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Recipharm
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Siegfried Holding
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Wu Xi App Tec
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Samsung Biologics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fujifilm Diosynth Biotechnologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Boehringer Ingelheim Bio Xcellence
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Patheon
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Corden Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Ajinomoto Bio- Pharma Services
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alcami Corporation
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Piramal Pharma Solutions
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Jubilant Hollister Stier
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cambrex Corporation
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 AMRI Global
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Thermo Fisher Scientific
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vetter Pharma International
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 PCI Pharma Services
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 LSNE Contract Manufacturing
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us